公开(公告)号：US20210317224A1

公开(公告)日：2021-10-14

申请号：US17286437

申请日：2020-08-12

Applicant: I-Mab Biopharma US Limited ,  ABL Bio Inc.

Inventor： Wenqing Jiang ,  Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Eunyoung Park ,  Eunsil Sung ,  Byungje Sung

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

公开(公告)号：US11261259B2

公开(公告)日：2022-03-01

申请号：US17286437

申请日：2020-08-12

Applicant: I-Mab Biopharma US Limited ,  ABL Bio Inc.

Inventor： Wenqing Jiang ,  Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Eunyoung Park ,  Eunsil Sung ,  Byungje Sung

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

公开(公告)号：US12195538B2

公开(公告)日：2025-01-14

申请号：US17298741

申请日：2019-02-15

Applicant: ABL BIO INC. ,  I-MAB BIOPHARMA US LIMITED

Inventor： Eunyoung Park ,  Yangsoon Lee ,  Hyejin Chung ,  Eunsil Sung ,  Jiseon Yoo ,  Minji Park ,  Yong-Gyu Son ,  Hyoju Choi ,  Eunjung Kim ,  Jaeho Jung ,  Weon-Kyoo You ,  Sang Hoon Lee ,  Lei Fang ,  Wenqing Jiang

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/46

Abstract: The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

公开(公告)号：US20220348675A1

公开(公告)日：2022-11-03

申请号：US17683869

申请日：2022-03-01

Applicant: I-Mab Biopharma US Limited ,  ABL Bio Inc.

Inventor： Wenqing Jiang ,  Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Eunyoung Park ,  Eunsil Sung ,  Byungje Sung

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

公开(公告)号：US20200071403A1

公开(公告)日：2020-03-05

申请号：US16687387

申请日：2019-11-18

Applicant: I-MAB Biopharma US Limited

Inventor： Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Jingwu Zang ,  Wenqing Jiang ,  Yongqiang Wang

IPC: C07K16/28 ,  A61K35/17 ,  A61P37/04 ,  A61P35/00

Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.

公开(公告)号：US11414485B2

公开(公告)日：2022-08-16

申请号：US16687387

申请日：2019-11-18

Applicant: I-MAB Biopharma US Limited

Inventor： Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Jingwu Zang ,  Wenqing Jiang ,  Yongqiang Wang

IPC: C07K16/28 ,  A61P35/00 ,  A61P37/04 ,  A61K35/17 ,  A61K39/00

Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.

公开(公告)号：US12173070B2

公开(公告)日：2024-12-24

申请号：US17269784

申请日：2019-08-21

Applicant: ABL BIO INC.

Inventor： Eunyoung Park ,  Yangsoon Lee ,  Uijung Jung ,  YoungKwang Kim ,  Yeun Ju Kim ,  Youngdon Pak ,  Sang Hoon Lee ,  Weon-Kyoo You ,  Jaeho Jung ,  Lei Fang ,  Wenqing Jiang

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.

公开(公告)号：US20230192861A1

公开(公告)日：2023-06-22

申请号：US17778382

申请日：2020-11-23

Applicant: ABL BIO INC. ,  I-MAB

Inventor： Eunsil Sung ,  Eunyoung Park ,  Jaehyoung Jeon ,  Junhyun Jeong ,  Daehae Song ,  Sunju Lee ,  Lei Fang ,  Wenqing Jiang ,  Feifei Cui

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2827 ,  C07K16/2878 ,  A61P35/00 ,  C07K2317/31 ,  C07K2317/24 ,  C07K2317/21 ,  C07K2317/92 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2317/55 ,  C07K2317/732 ,  A61K2039/505

Abstract: The present disclosure provides an anti-PD-L1/anti-B7-H3 multispecific antibody capable to effectively block the interaction between PD-L1 and its receptor PD-1, and suppress the T-cell inhibitory effect of B7-H3 protein. The multispecific antibody may have high binding affinity to both of a PD-L1 protein and a B7-H3 protein.